| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | -0.074 | 0.6 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.03 | 0.6 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.029 | 0.6 |